Literature DB >> 2329560

Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents.

K R Horspool1, M F Stevens, C G Newton, E Lunt, R J Walsh, B L Pedgrift, G U Baig, F Lavelle, C Fizames.   

Abstract

The preparation of 3-(2-chlorethyl)-4-oxo-3H-imidazo[5,1-d]-1,2,3,5- tetrazine-8-carboxylic acid, a key derivative of mitozolomide in our exploration of the structure-activity relationships of this class of antitumor agents, is described. The facile conversion to the 8-carbonyl chloride gave a derivative that reacted preferentially with nucleophiles at the 8-position rather than at the reactive 4-oxo group, allowing the preparation of a wide range of ester, thioester, amide (including an amide derived from an amino acid), hydroxamic acid, hydrazide and sulfoximide, azide and diazoacetyl derivatives. The in vivo activity is presented of a range of these compounds against TLX5 lymphoma and L1210 leukemia cell lines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2329560     DOI: 10.1021/jm00167a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.

Authors:  L L Tsang; P B Farmer; A Gescher; J A Slack
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression.

Authors:  Leroy Shervington; Oliver Ingham; Amal Shervington
Journal:  RSC Adv       Date:  2020-05-06       Impact factor: 4.036

3.  The medicinal chemistry of imidazotetrazine prodrugs.

Authors:  Catherine L Moody; Richard T Wheelhouse
Journal:  Pharmaceuticals (Basel)       Date:  2014-07-10

4.  Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.

Authors:  Riley L Svec; Lucia Furiassi; Christine G Skibinski; Timothy M Fan; Gregory J Riggins; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2018-11-08       Impact factor: 5.100

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.